BioSpace News Archive

Invibio Biomaterial Solutions, part of Victrex plc, a pioneer in the development of PEEK biomaterial solutions, announced a new collaboration with Paragon Medical, a medical device contract design manufacturer with over a century of combined expertise in high-precision manufacturing, advanced engineering and design support, to manufacture composite PEEK-OPTIMA™ Ultra-Reinforced medical trauma devices.

Disc Medicine, Inc. today presented preliminary findings from its ongoing, Phase 2 open-label BEACON trial evaluating bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) at the European Hematology Association (EHA) 2023 Congress in Frankfurt, Germany.

Praxis Precision Medicines , Inc. today announced the outcomes from a recent end-of-Phase 2 meeting with the U. S. Food and Drug Administration (FDA) regarding plans to advance ulixacaltamide into Phase 3 for essential tremor (ET).

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 7, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 19,400 shares of its common stock to six new employees, consisting of stock options to purchase an aggregate of 9,700 shares of common stock.

Vor Bio, a clinical-stage cell and genome engineering company, presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia.

Zomedica Corp. announced today the launch of the revolutionary TRUVIEW TM digital microscopy platform, featuring the proprietary TRUprep TM system that automatically prepares slides, along with LiquiView TM liquid lens technology that provides best-in-class images.

Notable Labs, Inc. today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens.

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company’s Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full.

TPG and AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices.

Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to four new employees as approved by the Compensation Committee of Codexis’s Board of Directors.